CA3026024C - Beta 3 adrenergic receptor modulators useful in the treatment or prevention of disorders associated with these - Google Patents

Beta 3 adrenergic receptor modulators useful in the treatment or prevention of disorders associated with these

Info

Publication number
CA3026024C
CA3026024C CA3026024A CA3026024A CA3026024C CA 3026024 C CA3026024 C CA 3026024C CA 3026024 A CA3026024 A CA 3026024A CA 3026024 A CA3026024 A CA 3026024A CA 3026024 C CA3026024 C CA 3026024C
Authority
CA
Canada
Prior art keywords
heart
failure
heart failure
2failure
beta
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA3026024A
Other languages
English (en)
French (fr)
Other versions
CA3026024A1 (en
Inventor
Thuy-Anh Tran
Quyen-Quyen Do
Brett Ullman
Maiko Nagura
Anthony C Blackburn
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Arena Pharmaceuticals Inc
Original Assignee
Arena Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arena Pharmaceuticals Inc filed Critical Arena Pharmaceuticals Inc
Publication of CA3026024A1 publication Critical patent/CA3026024A1/en
Application granted granted Critical
Publication of CA3026024C publication Critical patent/CA3026024C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
CA3026024A 2016-06-06 2017-06-05 Beta 3 adrenergic receptor modulators useful in the treatment or prevention of disorders associated with these Active CA3026024C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662346293P 2016-06-06 2016-06-06
US62/346,293 2016-06-06
PCT/US2017/035867 WO2017214002A1 (en) 2016-06-06 2017-06-05 Modulators of the beta-3 adrenergic receptor useful for the treatment or prevention of disorders related thereto

Publications (2)

Publication Number Publication Date
CA3026024A1 CA3026024A1 (en) 2017-12-14
CA3026024C true CA3026024C (en) 2024-07-02

Family

ID=59067920

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3026024A Active CA3026024C (en) 2016-06-06 2017-06-05 Beta 3 adrenergic receptor modulators useful in the treatment or prevention of disorders associated with these

Country Status (29)

Country Link
US (5) US20190284200A1 (enExample)
EP (1) EP3464292B8 (enExample)
JP (3) JP6771246B2 (enExample)
KR (2) KR20190026731A (enExample)
CN (1) CN109563103B (enExample)
AR (1) AR108772A1 (enExample)
AU (2) AU2017278102B2 (enExample)
CA (1) CA3026024C (enExample)
CL (1) CL2018003451A1 (enExample)
CO (1) CO2019000041A2 (enExample)
CR (1) CR20180595A (enExample)
DK (1) DK3464292T3 (enExample)
EA (1) EA201892817A1 (enExample)
EC (1) ECSP19001018A (enExample)
ES (1) ES2929737T3 (enExample)
IL (2) IL289378B (enExample)
MA (2) MA44037B1 (enExample)
MX (2) MX387995B (enExample)
MY (1) MY195982A (enExample)
NI (1) NI201800130A (enExample)
NZ (1) NZ749202A (enExample)
PE (1) PE20190445A1 (enExample)
PH (1) PH12018502550B1 (enExample)
PT (1) PT3464292T (enExample)
SG (1) SG11201810788QA (enExample)
TN (1) TN2018000391A1 (enExample)
TW (2) TWI752963B (enExample)
UA (1) UA125120C2 (enExample)
WO (1) WO2017214002A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA44037B1 (fr) 2016-06-06 2020-03-31 Arena Pharm Inc Modulateurs du récepteur adrénergique bêta 3 utile dans le traitement ou la prévention de troubles associés à ceux-ci
DK3448859T3 (da) 2017-03-20 2019-09-23 Forma Therapeutics Inc Pyrrolopyrrolsammensætninger som pyruvatkinase- (pkr) aktivatorer
ES2953576T3 (es) * 2017-12-06 2023-11-14 Arena Pharm Inc Moduladores del receptor beta-3 adrenérgico útiles para el tratamiento o la prevención de la insuficiencia cardíaca y los trastornos relacionados con la misma
JP7450610B2 (ja) 2018-09-19 2024-03-15 ノヴォ・ノルディスク・ヘルス・ケア・アーゲー ピルビン酸キナーゼｒの活性化
WO2020061378A1 (en) 2018-09-19 2020-03-26 Forma Therapeutics, Inc. Treating sickle cell disease with a pyruvate kinase r activating compound
MX2022003254A (es) 2019-09-19 2022-04-18 Forma Therapeutics Inc Composiciones activadoras de piruvato cinasa r (pkr).
US12128035B2 (en) 2021-03-19 2024-10-29 Novo Nordisk Health Care Ag Activating pyruvate kinase R
JP2023024954A (ja) * 2021-08-09 2023-02-21 アリーナ ファーマシューティカルズ， インコーポレイテッド ベータ－３アドレナリン作動性受容体に関連する障害の処置または予防に有用なベータ－３アドレナリン作動性受容体のモジュレーター
WO2023026185A1 (en) * 2021-08-26 2023-03-02 Arena Pharmaceuticals, Inc. Modulators of the beta-3 adrenergic receptor for the treatment or prevention of renal cystic disease and cardiorenal syndrome
US20240409548A1 (en) * 2021-10-06 2024-12-12 Arena Pharmaceuticals, Inc. Modulators of the beta-3 adrenergic receptor useful for the treatment or prevention of disorders related thereto
EP4479384A1 (en) * 2022-02-14 2024-12-25 Biogen MA Inc. Emopamil-binding protein inhibitors and uses thereof
CN114539103B (zh) * 2022-03-21 2023-04-07 佳木斯黑龙农药有限公司 2-二氟乙氧基-6-三氟甲基苯磺酰氯的合成方法
CN116178220A (zh) * 2022-12-13 2023-05-30 爱斯特（成都）生物制药股份有限公司 一种制备(2s)-2-[[3-(甲基磺酰基l)苯氧基]甲基]环氧乙烷的方法

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3028340C2 (de) * 1980-07-25 1987-02-05 Dr. Willmar Schwabe GmbH & Co, 7500 Karlsruhe Amino-desoxy-1.4;3.6-dianhydro-hexit-nitrate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Zubereitungen
US5254595A (en) 1988-12-23 1993-10-19 Elf Sanofi Aryloxypropanolaminotetralins, a process for their preparation and pharmaceutical compositions containing them
FR2751646B1 (fr) 1996-07-23 1999-01-22 Sanofi Sa Phenoxypropanolamine a action antagoniste beta3-adrenergique
AU7738298A (en) 1996-12-19 1998-07-15 Agrevo Uk Limited Chromones useful as fungicides
FR2780057B1 (fr) * 1998-06-18 2002-09-13 Sanofi Sa Phenoxypropanolamines, procede pour leur preparation et compositions pharmaceutiques les contenant
JP4782342B2 (ja) * 1999-12-17 2011-09-28 サノフィ−アベンティス フェノキシプロパノールアミン類、それらの製造方法およびそれらを含む医薬組成物
DE20204129U1 (de) 2002-03-15 2002-07-25 Wella Ag, 64295 Darmstadt Mittel zur Färbung von Keratinfasern mit Chinolinium-Farbstoffen
WO2005092860A1 (en) * 2004-03-23 2005-10-06 Pfizer Limited Compounds for the treatment of diseases
EP1833480A2 (en) * 2004-11-30 2007-09-19 Artesian Therapeutics, Inc. Cardiotonic compounds with inhibitory activity against beta-adrenergic receptors and phosphodiesterase
US8697674B2 (en) 2004-12-29 2014-04-15 Naturon, Inc. Xanthurenic acid derivative pharmaceutical compositions and methods related thereto
WO2008094507A2 (en) 2007-01-26 2008-08-07 Cellicon Biotechnologies, Inc. Novel fusion compounds
US8039505B2 (en) 2007-04-11 2011-10-18 University Of Utah Research Foundation Compounds for modulating T-cells
US8722851B2 (en) 2007-11-02 2014-05-13 Pain Therapeutics, Inc. Analgesia with minimal tolerance and dependence by a mu opioid receptor agonist that also binds filamin A
US20100279997A1 (en) 2009-05-04 2010-11-04 Lindsay Burns Barbier Analgesic that binds filamin a
AU2009308702B2 (en) 2008-10-31 2015-05-28 Pain Therapeutics, Inc. Filamin A binding anti-inflammatory and analgesic
AU2009308769B2 (en) 2008-10-31 2015-03-12 Pain Therapeutics, Inc. Filamin A-binding anti-inflammatory analgesic
EP2367830A1 (en) * 2008-11-21 2011-09-28 Pfizer Inc. 1-oxa-8-azaspiro [4, 5] decane- 8 -carboxamide compounds as faah inhibitors
EP2563764B1 (en) * 2010-04-26 2015-02-25 Merck Sharp & Dohme Corp. Novel spiropiperidine prolylcarboxypeptidase inhibitors
JP5795799B2 (ja) * 2010-07-23 2015-10-14 メルク・シャープ・エンド・ドーム・コーポレイション 新規なピロリジン由来ベータ３アドレナリン作動性受容体アゴニスト
JP2012092038A (ja) 2010-10-26 2012-05-17 F Hoffmann La Roche Ag 糖尿病、糖尿病関連疾患又は糖尿病性合併症の予防又は治療剤
DK2882428T3 (en) 2012-07-13 2019-04-15 Pain Therapeutics Inc PROCEDURE TO INHIBIT TAU PHOSPHORIZATION
EP2872899B1 (en) 2012-07-13 2018-07-11 Pain Therapeutics, Inc. Alzheimer's disease assay in a living patient
GB201405359D0 (en) 2014-03-25 2014-05-07 Univ Liverpool Synthetic process
MA44037B1 (fr) 2016-06-06 2020-03-31 Arena Pharm Inc Modulateurs du récepteur adrénergique bêta 3 utile dans le traitement ou la prévention de troubles associés à ceux-ci
ES2953576T3 (es) * 2017-12-06 2023-11-14 Arena Pharm Inc Moduladores del receptor beta-3 adrenérgico útiles para el tratamiento o la prevención de la insuficiencia cardíaca y los trastornos relacionados con la misma

Also Published As

Publication number Publication date
US20200270264A1 (en) 2020-08-27
CN109563103A (zh) 2019-04-02
KR20190026731A (ko) 2019-03-13
IL289378A (en) 2022-02-01
EP3464292B8 (en) 2022-10-26
ES2929737T3 (es) 2022-12-01
NZ749202A (en) 2022-07-01
ECSP19001018A (es) 2019-02-28
TW202237619A (zh) 2022-10-01
US20190389875A1 (en) 2019-12-26
AU2021206809B2 (en) 2023-01-05
JP2019518079A (ja) 2019-06-27
TN2018000391A1 (en) 2020-06-15
CN109563103B (zh) 2022-05-27
KR20220025128A (ko) 2022-03-03
US10927123B2 (en) 2021-02-23
US20190284200A1 (en) 2019-09-19
AR108772A1 (es) 2018-09-26
TWI784840B (zh) 2022-11-21
JP7449329B2 (ja) 2024-03-13
UA125120C2 (uk) 2022-01-12
MX2021014043A (es) 2022-02-21
AU2021206809A1 (en) 2021-08-12
MA45150A (fr) 2021-05-05
PE20190445A1 (es) 2019-03-29
TWI752963B (zh) 2022-01-21
EP3464292A1 (en) 2019-04-10
US20210340154A1 (en) 2021-11-04
CL2018003451A1 (es) 2019-02-22
NI201800130A (es) 2019-06-13
KR102408272B1 (ko) 2022-06-10
MX2018015124A (es) 2019-09-09
JP2020203945A (ja) 2020-12-24
DK3464292T3 (da) 2022-10-31
CA3026024A1 (en) 2017-12-14
JP7083087B2 (ja) 2022-06-10
IL289378B (en) 2022-09-01
US10662200B2 (en) 2020-05-26
TW201803877A (zh) 2018-02-01
MA44037B1 (fr) 2020-03-31
EP3464292B1 (en) 2022-09-21
IL263148B (en) 2022-02-01
PH12018502550A1 (en) 2019-11-04
US20190292196A1 (en) 2019-09-26
SG11201810788QA (en) 2018-12-28
JP2022089984A (ja) 2022-06-16
CR20180595A (es) 2019-04-09
CO2019000041A2 (es) 2019-04-30
MX387995B (es) 2025-03-19
WO2017214002A1 (en) 2017-12-14
AU2017278102A1 (en) 2019-01-17
PH12018502550B1 (en) 2023-01-27
JP6771246B2 (ja) 2020-10-21
IL263148A (en) 2018-12-31
BR112018075201A2 (pt) 2019-03-19
US10479797B2 (en) 2019-11-19
PT3464292T (pt) 2022-11-15
MY195982A (en) 2023-02-27
US11560386B2 (en) 2023-01-24
MA44037A1 (fr) 2019-05-31
AU2017278102B2 (en) 2021-04-29
EA201892817A1 (ru) 2019-06-28

Similar Documents

Publication Publication Date Title
CA3026024C (en) Beta 3 adrenergic receptor modulators useful in the treatment or prevention of disorders associated with these
PH12021551923A1 (en) Compounds, compositions and methods
WO2009076580A3 (en) Compositions and methods for the treatment and prevention of cardiovascular diseases
WO2018121559A8 (zh) 甘露糖醛二酸的组合物
WO2016175555A8 (en) Novel 4-methoxy pyrrole derivatives or salts thereof and pharmaceutical composition comprising the same
CO2021002768A2 (es) Compuestos de 2,6-diaminopiridina
AR114156A1 (es) MODULADORES DEL RECEPTOR ADRENÉRGICO b-3 ÚTILES PARA EL TRATAMIENTO O LA PREVENCIÓN DE TRASTORNOS RELACIONADOS CON ESTE
AR067604A1 (es) Resinas epoxi modificadas que comprenden el producto de reaccion de un compuesto derivado de biomasa y una resina epoxi dispersiones acuosas y recubrimientos que comprenden dichas resinas
CL2008001205A1 (es) Compuestos derivados de biciclo[2.2.2]octeno; composicion farmaceutica que los contiene; y uso en el tratamiento o prevencion de angina cronica estable, hipertension, isquemia renal y cardiaca, arritmias cardiacas, hipertrofia cardiaca y falla congestiva del corazon.
MX2020007994A (es) Derivados de triazolopirimidina para usar como inhibidores de ghrelin o-aciltransferasa (goat).
MX366418B (es) Papel tisu crepado suave.
WO2008101247A3 (en) 6 ' substituted indole and indazole derivatives having 5-ht6 receptor affinity
CA3128691C (en) Methods of improving myocardial performance in fontan patients using udenafil compositions
EP4603588A3 (en) Methods and compositions for controlling cardiac fibrosis and remodeling
BR112015005185A2 (pt) composição aquosa de revestimento; substrato e método de preparar uma composição aquosa de revestimento
JOP20180111B1 (ar) منظمات مستقبل أدريناليني بيتا-3 مفيدة لمعالجة او الوقاية من اضطرابات مرتبطة بها
WO2016023028A3 (en) G protein-coupled receptor kinase 2 inhibitors and methods for use of the same
WO2020123096A3 (en) 2xxx aluminum alloys
WO2022159808A3 (en) Functionalized long-chain carboxylic acids, and their use for treatment of disease
WO2009045539A3 (en) Peg-corticosteroid conjugates
WO2017067497A3 (zh) 一种单取代或多取代的酯水双亲性竹红菌素衍生物及其制备方法和应用
WO2020243572A3 (en) Pan-neuraminidase inhibiting antibodies
MX2020001481A (es) Novedosos compuestos que activan la ruta nrf2.
WO2022056068A8 (en) Small molecule inhibitors of enpp1
WO2008069890A3 (en) Adrenal grk2 activity as a therapeutic target for heart failure

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220314

EEER Examination request

Effective date: 20220314

EEER Examination request

Effective date: 20220314

EEER Examination request

Effective date: 20220314

EEER Examination request

Effective date: 20220314

EEER Examination request

Effective date: 20220314

EEER Examination request

Effective date: 20220314

EEER Examination request

Effective date: 20220314